Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tyrosinase and TRP-1 Peptide Vaccines in Metastatic Melanoma
NCT00019383Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 1998
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of tyrosinase peptide and tyrosinase-related protein-1 in melanoma (4 arms), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate and Immunologic Response. Started Jan 1998; status: completed.
02
Drugs
tyrosinase peptidetyrosinase-related protein-1
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019383.